634151-60-3

Upstream product

• 433939-99-2 Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-Aze-Pab(2,6-diF)(Teoc) 
• 631-61-8 ammonium acetate 
• 433939-99-2 Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-Aze-Pab(2,6-diF)(Teoc) 
• 433939-99-2 Ph(3-Cl)(5-OCHF₂)-(R)-CH(OH)C(O)-Aze-Pab(2,6-diF)(Teoc) 

Relevant academic research and scientific papers

Mandelic acid derivatives and their use as throbin inhibitors

There is provided a compound of formula I wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION

According to the present invention there is provided an immediate release pharmaceutical formulation comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituen

MODIFIED RELEASE PHARMACEUTICAL FORMULATION

A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1 represents C?1-2#191 alkyl substituted by one or more fluoro substituents;R2 represents hydrogen, hydroxy, methoxy

PHARMACEUTICAL COMBINATION

There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.